The Indian healthcare sector is expected to reach Rs 19,56,920 crore (US$ 280 billion) by 2020. Rising income level, greater health awareness, increased precedence of lifestyle diseases and improved access to insurance would be the key contributors to growth

– Revamping the existing guidelines for setting up medical and pharmaceutical education and research  methods as per future methodologies. There is a need to encourage case-based learning and research. This method of education and research  gives a great difference in learning outcomes. Emphases needs to be for exchange programs of students and research fellows both in  education and research between  US and India.   
– Indian Pharmaceuticals is a sunrise industry with a competitive advantage for India globally. we should leverage India’s position by unleashing entrepreneur spirit the bullish outlook for health care segment is now taking India in a forward momentum. The market size of India in Pharmaceuticals alone is estimated to be $100 billion and medical devices is $25 billion by 2025. Now with amendment in FDI policy where one can invest up to 100% specially if it is medical devices segment where India is  importing 80% of medical devices. 
– India is looking towards growth tenure as 55 billion US dollar of product line is going off patents and this will certainly help India accelerate a higher market share and exports. America, Europe, Japan, South Korea and many countries are planning to shift their manufacturing units out of China. India can and can become the worlds largest hub for Healthcare manufacturing and distribution. Now is the time for Industry Leaders, academia and Government to come together cash in on opportunity.